Related Experiment Video

Updated: Jun 16, 2026

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
09:08

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

Treatment of cutaneous lymphomas: today and tomorrow

D S Mestel1, M Beyer, M Steinhoff

  • 1Department of Dermatology Venereology and Allergy, Skin Cancer Center, Charité Universitaetsmedizin Berlin, Germany. dominik.mestel@charite.de

Actas Dermo-Sifiliograficas
|January 26, 2010
PubMed

Insights

Conventional treatments for cutaneous lymphomas offer limited long-term survival benefits. Emerging targeted therapies, including monoclonal antibodies and fusion proteins, show promise for improved outcomes in advanced stages.

Area of Science:

  • Dermatology
  • Oncology
  • Immunology

Background:

  • Primary cutaneous lymphomas (T- and B-cell) have various treatment options.
  • Conventional therapies often provide only temporary remission, especially in advanced stages, without improving overall survival.
  • There is a significant need for novel therapeutic strategies.

Purpose of the Study:

  • To review conventional treatment modalities for primary cutaneous lymphomas.
  • To discuss emerging drugs and novel therapeutic strategies targeting specific tumor mechanisms.
  • To highlight treatments that have shown promising results in clinical trials.

Main Methods:

  • Literature review of conventional and emerging therapies for cutaneous lymphomas.
  • Discussion of targeted agents such as monoclonal antibodies, histone-deacetylase inhibitors, proteasome inhibitors, and fusion proteins.
  • Analysis of clinical trial data for novel therapeutic strategies.

Main Results:

  • Conventional treatments are often insufficient for long-term remission and survival in advanced cutaneous lymphomas.
  • Emerging targeted therapies demonstrate potential for more specific tumor attack.
  • Several new therapeutic strategies have shown promising results in clinical trials.

Conclusions:

  • Novel therapeutic strategies are crucial for improving outcomes in primary cutaneous lymphomas.
  • Targeted therapies offer a more promising approach compared to conventional treatments, particularly in advanced disease.
  • Further research and clinical application of these emerging drugs are warranted.

More Related Videos

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

Related Concept Videos

Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...